Investment case
Vivani Medical, Inc.
VANI · 10 developments mapped · last assessed 2026-08-31
Market Ontology has mapped 10 macro, policy, and market developments to Vivani Medical, Inc. since 2026-08-30. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for VANI yet, so no modelled value is shown. The VANI valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run VANI on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Strongest support
Novo Nordisk Introduces Oral Wegovy and Vivani Implant Partnership
Direct partnership with a major pharmaceutical company for a key product, validating technology and providing potential future revenue streams.
· Moves technology validation and adoption, future licensing or milestone payments, ability to secure additional partnerships
What changed, by assumption
- 2026-08-30Novo Nordisk Launches Oral Wegovy and Partners with Vivani for GLP-1 Implants
- 2026-08-30Novo Nordisk Launches Oral Wegovy and Partners with Vivani on Implant Delivery
- 2026-08-31Novo Nordisk Advances Oral Wegovy and Implant Program Against Eli Lilly Lead
- 2026-08-31Novo Nordisk Introduces Oral Wegovy and Vivani Implant Partnership
- 2026-08-30Novo Nordisk Deploys Oral Wegovy and Vivani Implant Delivery in GLP-1 Race
- 2026-08-30Novo Nordisk Deploys Oral Wegovy and Vivani Delivery Partnership
- 2026-08-30Novo Nordisk Introduces Oral Wegovy and Partners with Vivani on GLP-1 Implant
Assumption changes
Full ledger →| Date | Assumption | Direction | Why | Conf. |
|---|---|---|---|---|
| 2026-07-07 | Valuation multiple | Bullish | Target re-rates to bid premium until close. | 0.70 |
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-08-31 | Novo Nordisk Advances Oral Wegovy and Implant Program Against Eli Lilly Lead | Bullish | 1-5y | 0.60 |
| 2026-08-31 | Novo Nordisk advances Wegovy pill formulation and Vivani implant partnership | Bullish | 3-12m | 0.70 |
| 2026-08-31 | Novo Nordisk advances oral Wegovy and Vivani implant partnership in GLP-1 race | Bullish | 1-5y | 0.70 |
| 2026-08-31 | Novo Nordisk Introduces Oral Wegovy and Vivani Implant Partnership | Bullish | 1-3m | 0.90 |
| 2026-08-30 | Novo Nordisk Introduces Wegovy Pill and Partners on Long-Acting Implant | Bullish | 3-12m | 0.70 |
| 2026-08-30 | Novo Nordisk Deploys Oral Wegovy and Vivani Implant Delivery in GLP-1 Race | Bullish | 3-12m | 0.90 |
| 2026-08-30 | Novo Nordisk Launches Oral Wegovy and Partners with Vivani for GLP-1 Implants | Bullish | 3-12m | 0.90 |
| 2026-08-30 | Novo Nordisk Deploys Oral Wegovy and Vivani Delivery Partnership | Bullish | 3-12m | 0.90 |
| 2026-08-30 | Novo Nordisk Launches Oral Wegovy and Partners with Vivani on Implant Delivery | Bullish | 1-5y | 0.70 |
| 2026-08-30 | Novo Nordisk Introduces Oral Wegovy and Partners with Vivani on GLP-1 Implant | Bullish | 1-5y | 0.90 |